American Journal of HematologyVolume 84, Issue 10 p. 697-698 CorrespondenceFree Access Monitoring of cytomegalovirus reactivation during induction and nontransplant consolidation of acute leukemia† Monia Lunghi, Monia Lunghi Division of Hematology, Amedeo Avogadro, University of Eastern Piedmont and Ospedale, Maggiore della Carità, Novara, ItalySearch for more papers by this authorPaola Riccomagno, Paola Riccomagno Division of Hematology, Amedeo Avogadro, University of Eastern Piedmont and Ospedale, Maggiore della Carità, Novara, ItalySearch for more papers by this authorLorenzo De Paoli, Lorenzo De Paoli Division of Hematology, Amedeo Avogadro, University of Eastern Piedmont and Ospedale, Maggiore della Carità, Novara, ItalySearch for more papers by this authorChiara Vendramin, Chiara Vendramin Division of Hematology, Amedeo Avogadro, University of Eastern Piedmont and Ospedale, Maggiore della Carità, Novara, ItalySearch for more papers by this authorAnnarita Conconi, Annarita Conconi Division of Hematology, Amedeo Avogadro, University of Eastern Piedmont and Ospedale, Maggiore della Carità, Novara, ItalySearch for more papers by this authorGianluca Gaidano, Gianluca Gaidano Division of Hematology, Amedeo Avogadro, University of Eastern Piedmont and Ospedale, Maggiore della Carità, Novara, ItalySearch for more papers by this authorDavide Rossi, Davide Rossi Division of Hematology, Amedeo Avogadro, University of Eastern Piedmont and Ospedale, Maggiore della Carità, Novara, ItalySearch for more papers by this author Monia Lunghi, Monia Lunghi Division of Hematology, Amedeo Avogadro, University of Eastern Piedmont and Ospedale, Maggiore della Carità, Novara, ItalySearch for more papers by this authorPaola Riccomagno, Paola Riccomagno Division of Hematology, Amedeo Avogadro, University of Eastern Piedmont and Ospedale, Maggiore della Carità, Novara, ItalySearch for more papers by this authorLorenzo De Paoli, Lorenzo De Paoli Division of Hematology, Amedeo Avogadro, University of Eastern Piedmont and Ospedale, Maggiore della Carità, Novara, ItalySearch for more papers by this authorChiara Vendramin, Chiara Vendramin Division of Hematology, Amedeo Avogadro, University of Eastern Piedmont and Ospedale, Maggiore della Carità, Novara, ItalySearch for more papers by this authorAnnarita Conconi, Annarita Conconi Division of Hematology, Amedeo Avogadro, University of Eastern Piedmont and Ospedale, Maggiore della Carità, Novara, ItalySearch for more papers by this authorGianluca Gaidano, Gianluca Gaidano Division of Hematology, Amedeo Avogadro, University of Eastern Piedmont and Ospedale, Maggiore della Carità, Novara, ItalySearch for more papers by this authorDavide Rossi, Davide Rossi Division of Hematology, Amedeo Avogadro, University of Eastern Piedmont and Ospedale, Maggiore della Carità, Novara, ItalySearch for more papers by this author First published: 06 July 2009 https://doi.org/10.1002/ajh.21494Citations: 4 † Conflict of interest: Nothing to report. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Meijer E,Boland GJ,Verdonck LF. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Mcrobiol Rev 2003; 16: 647– 657. 2 Suciu S,Mandelli F,de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood 2003; 102: 1232– 1240. 3 Amadori S,Suciu S,Jehn U, et al.; EORTC/GIMEMA Leukemia Group. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: Final results of AML-13, a randomized phase-3 study. Blood 2005; 106: 27– 34. 4 Mayer RJ,Davis RB,Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331: 896– 903. 5 Cimino G,Elia L,Mancini M, et al. Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: Absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome. Blood 2003; 102: 2014– 2020. 6 Borthakur G,Lin E,Faderl S, et al. Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies. Cancer 2007; 110: 2478– 2483. 7 O'Brien SM,Keating MJ,Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 2006; 7: 125– 130. Citing Literature Volume84, Issue10October 2009Pages 697-698 ReferencesRelatedInformation